Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 260-906-9 | CAS number: 57693-14-8
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012-06-12 to 2012-08-21
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- (Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany)
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- Trisodium bis[3-hydroxy-4-[(2-hydroxy-1-naphthyl)azo]-7-nitronaphthalene-1-sulphonato(3-)]chromate(3-)
- EC Number:
- 260-906-9
- EC Name:
- Trisodium bis[3-hydroxy-4-[(2-hydroxy-1-naphthyl)azo]-7-nitronaphthalene-1-sulphonato(3-)]chromate(3-)
- Cas Number:
- 57693-14-8
- Molecular formula:
- C40H20CrN6O14S2.3Na
- IUPAC Name:
- trisodium bis[3-hydroxy-4-[(2-hydroxy-1-naphthyl)azo]-7-nitronaphthalene-1-sulphonato(3-)]chromate(3-)
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Full barrier in an air-conditioned room
- Temperature: 22 ± 3 °C
- Relative humidity: 55 ± 10 %
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: 10 hour
- Free access to Altromin 1324 maintenance diet for rats and mice (lot no. . 0715)
- Free access to tap water, sulphur acidified to a pH value of approximately 2.8 (drinking water, municipal residue control, microbiological controls at regular intervals)
- The animals were kept individually in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding (lot no. 261111)
- Certificates of food, water and bedding are filed at BSL BIOSERVICE
- Adequate acclimatisation period (at least five days) under laboratory conditions
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- water
- Remarks:
- Aqua ad injectionem (Diprom, lot no. 10952-1, expiry date: 09/2013)
- Details on dermal exposure:
- Preparation of animals:
The animals were marked for individual identification by tail painting.
Approximately 24 hours before the test, the fur was removed from the dorsal area of the trunk using an electric clipper.
Care was taken to avoid abrading the skin, and only animals with healthy intact skin were used.
No less than 10 % of the body surface was cleared for the application.
Prior to the application a detailed clinical observation was made of all animals.
Application:
The test item was applied at a single dose, uniformly over an area which was approximately 10 % of the total body surface.
The test item was held in contact with the skin by a dressing throughout a 24-hour period.
The dressing consisted of a gauze-dressing and non-irritating tape and was fixed with an additional dressing in a suitable manner. - Duration of exposure:
- The test item was held in contact with the skin throughout a 24-hour period.
At the end of the exposure period the residual test item was removed using aqua ad injectionem. - Doses:
- The test item was applied at a single dose of 2000 mg/kg body weight to each animal considering the active component content of 86.5 %.
- No. of animals per sex per dose:
- 5 male and 5 female
- Control animals:
- not required
- Details on study design:
- Observation period: all animals were observed for 14 days after dosing.
Weight assessment: animals were weighed on day 1 (prior to the application) and on days 8 and 15.
Clinical examination: careful clinical examination was made several times on the day of dosing (at least once during the first 30 minutes and with special attention given during the first 4 hours post-dose). As soon as symptoms were noticed they were recorded.
Thereafter, the animals were observed for clinical signs once daily until the end of the observation period. All abnormalities were recorded.
Cageside observations included changes in the skin and fur, eyes and mucous membranes. Also respiratory, circulatory, autonomic and central nervous systems and somatomotor activity and behaviour pattern were examined. Attention was directed to observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Pathology: at the end of the observation period the surviving animals were sacrificed with an overdosage of pentobarbital injected intraperitoneally (Narcoren®, Merial) at the dosage of approximately 8 mL/kg bw. All animals were subjected to gross necropsy.
All gross pathological changes were recorded and in case of findings the tissues were preserved for a possible histopathological evaluation. The preserved tissues of which no histopathological evaluation was made will be discarded 3 months after the release of the final report unless otherwise agreed upon with the sponsor.
Evaluation of results: individual reactions of each animal were recorded at each time of observation; toxic response data were recorded by sex and dose level; nature, severity and duration of clinical observations were described; body weight changes were summarised in a tabular form. Necropsy findings were described. - Statistics:
- According to OECD guidelines, the biological relevance of the results is the criterion for the interpretation of results, a statistical evaluation of the results is not regarded as necessary.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- approximate LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- No mortality was observed
- Clinical signs:
- other: No treatment-related effects were observed.
- Gross pathology:
- No treatment-related effects were observed.
- Other findings:
- No erythema or oedema was observed.
Any other information on results incl. tables
Clinical signs of systemic toxicity – Individual data - males:
Animal |
Time |
Observations |
21/ male / |
during the whole observation period |
no signs of toxicity |
22/ male / |
during the whole observation period |
no signs of toxicity |
23/ male / |
during the whole observation period |
no signs of toxicity |
24/ male / |
during the whole observation period |
no signs of toxicity |
25/ male / |
during the whole observation period |
no signs of toxicity |
Clinical signs of systemic toxicity – individual data – females:
Animal |
Time |
Observations |
26/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
27/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
28/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
29/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
30/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
Skin irritation – individual data – males:
Day after start of application |
Animal No. 21 |
Animal No. 22 |
Animal No. 23 |
Animal No. 24 |
Animal No. 25 |
|||||
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
|
day 2 |
0/0 |
R |
0/0 |
R |
0/0 |
R |
0/0 |
R |
0/0 |
R |
day 3 |
0/0 |
R |
0/0 |
R |
0/0 |
R |
0/0 |
R |
0/0 |
R |
day 4 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 5 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 6 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 7 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 8 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 9 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 10 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 11 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 12 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 13 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 14 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 15 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Comments: E = erythema; O = oedema; 1, 2, 3, 4 = scoring system laid down in OECD guideline 404; R = residues of test item |
||||||||||
Skin irritation – individual data – females:
Day after start of application |
Animal No. 26 |
Animal No. 27 |
Animal No. 28 |
Animal No. 29 |
Animal No. 30 |
|||||
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
|
day 2 |
0/0 |
R |
0/0 |
R |
0/0 |
R |
0/0 |
R |
0/0 |
R |
day 3 |
0/0 |
R |
0/0 |
R |
0/0 |
R |
0/0 |
R |
0/0 |
R |
day 4 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 5 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 6 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 7 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 8 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 9 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 10 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 11 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 12 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 13 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 14 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
day 15 |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
0/0 |
nsf |
Comments: E = erythema; O = oedema; 1, 2, 3, 4 = scoring system laid down in OECD guideline 404; R = residues of test item |
||||||||||
Absolute body weights in g and body weight gain in %:
Dose: 2000 mg/kg body weight |
||||
Animal No. / Sex |
g |
g |
g |
% |
21 / male |
250 |
271 |
306 |
22 |
22 / male |
239 |
257 |
288 |
21 |
23 / male |
228 |
243 |
270 |
18 |
24 / male |
240 |
255 |
282 |
18 |
25 / male |
254 |
277 |
303 |
19 |
26 / female |
215 |
222 |
228 |
6 |
27 / female |
208 |
216 |
229 |
10 |
28 / female |
214 |
226 |
235 |
10 |
29 / female |
218 |
242 |
250 |
15 |
30 / female |
221 |
226 |
230 |
4 |
Macroscopic findings - individual data – males and females:
Dose: 2000 mg/kg bw |
||
Animal no. / |
Organ |
Macroscopic findings |
21 / male |
- |
nsf |
22 / male |
- |
nsf |
23 / male |
- |
nsf |
24 / male |
- |
nsf |
25 / male |
- |
nsf |
26 / female |
- |
nsf |
27 / female |
- |
nsf |
28 / female |
- |
nsf |
29 / female |
- |
nsf |
30 / female |
- |
nsf |
nsf = no specific findings
LD50:
Dose (unit)
|
No. of animals investigated |
No. of intercurrent deaths |
LD50 |
2000 mg/kg bw |
5 males |
0 |
> 2000 mg/kg bw |
2000mg/kg bw |
5 females |
0 |
> 2000 mg/kg bw |
Applicant's summary and conclusion
- Interpretation of results:
- other: not classified according to the CLP Regulation (EC 1272/2008)
- Conclusions:
- LD50 > 2000 mg/kg bw.
- Executive summary:
Method
Test substance was applied to 5 rats per sex at dose of 2000 mg/kg for a 24 h exposure duration.
Results
No death occurred.
Signs of toxicity related to dose level used, time of onset and duration: no treatment-related effects were observed.
Effect on organs (related to dose level): no treatment-related effects were observed.
Signs of irritation: no erythema or oedema was observed.
LD50 > 2000 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
